December 3rd, 2012
Selections from Richard Lehman’s Literature Review: December 3rd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and more.
November 14th, 2010
Emphatic Support for Eplerenone in NYHA Class II Heart Failure
Larry Husten, PHD
Aldosterone antagonists have proven beneficial in heart failure patients with moderate-to-severe symptoms and in MI patients with LV dysfunction and heart failure. Now EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) has extended these benefits to patients with systolic HF and mild symptoms. EMPHASIS HF randomized 2737 patients with NYHA class II […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?